Patrik Andersson

Patrik Andersson

Auto-generated profile, based on publicly available information

Patrik Andersson

Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2018 in Science Advances
Verified
Journal Article
Open access
PDF file
CÄC. Ämmälä
C. Ämmälä
WDW. J. Drury
W. J. Drury
LKL. Knerr
L. Knerr
IAI. Ahlstedt
I. Ahlstedt
PSP. Stillemark-Billton
P. Stillemark-Billton
SAShalini Andersson
Shalini Andersson
Receptor-dependent productive uptake of GLP1-conjugated antisense oligonucleotides occurs selectively in pancreatic β-cells.

28 December 2022 in Nucleic Acid Therapeutics
Verified
Journal Article
Open access
Aurélie GoyenvalleAurélie Goyenvalle
Aurélie Goyenvalle
CJCecilia Jimenez-Mallebrera
Cecilia Jimenez-Mallebrera
WRWilleke van Roon
Willeke van Roon
SSSabine Sewing
Sabine Sewing
AKArthur M. Krieg
Arthur M. Krieg
PAPatrik Andersson
Patrik Andersson
The nucleic acid therapeutics field has made tremendous progress in the past decades. Continuous advances in chemistry and design have led to many successful clinical applications, eliciting even more interest from researchers including both academic groups and drug development companies. Many preclinical studies in the field focus on improving the delivery of antisense oligonucleotide drugs (ONDs) and/or assessing their efficacy in target tissues, often neglecting the evaluation of toxicity, at least in early phases of development. A series of consensus recommendations regarding regulatory considerations and expectations have been generated by the Oligonucleotide Safety Working Group and the Japanese Research Working Group for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use S6 and Related Issues (WGS6) in several white papers. However, safety aspects should also be kept in sight in earlier phases while screening and designing OND to avoid subsequent failure in the development phase. Experts and members of the network “DARTER,” a COST Action funded by the Cooperation in Science and Technology of the EU, have utilized their collective experience working with OND, as well as their insights into OND-mediated toxicities, to generate a series of consensus recommendations to assess OND toxicity in early stages of preclinical research. In the past few years, several publications have described predictive assays, which can be used to assess OND-mediated toxicity in vitro or ex vivo to filter out potential toxic candidates before moving to in vivo phases of preclinical development, that is, animal toxicity studies. These assays also have the potential to provide translational insight since they allow a safety evaluation in human in vitro systems. Yet, small preliminary in vivo studies should also be considered to complement this early assessment. In this study, we summarize the state of the art and provide guidelines and recommendations on the different tests available for these early stage preclinical assessments.

1 February 2025 in Nucleic Acid Therapeutics
Verified
Journal Article
Open access
PAPatrik Andersson
Patrik Andersson
SBSebastien A. Burel
Sebastien A. Burel
HEHeather Estrella
Heather Estrella
JFJeffrey Foy
Jeffrey Foy
PHPeter H. Hagedorn
Peter H. Hagedorn
USUtsav Saxena
Utsav Saxena
Hybridization-dependent off-target (OffT) effects, occurring when oligonucleotides bind via Watson–Crick–Franklin hybridization to unintended RNA transcripts, remain a critical safety concern for oligonucleotide therapeutics (ONTs). Despite the importance of OffT assessment of clinical trial ONT candidates, formal guidelines are lacking, with only brief mentions in Japanese regulatory documents (2020) and US Food and Drug Administration (FDA) recommendations for hepatitis B virus treatments (2022). This article presents updated industry recommendations for assessing OffTs of ONTs, building upon the 2012 Oligonucleotide Safety Working Group (OSWG) recommendations and accounting for recent technological advancements. A new OSWG subcommittee, comprising industry experts in RNase H-dependent and steric blocking antisense oligonucleotides and small interfering RNAs, has developed a comprehensive framework for OffT assessment. The proposed workflow encompasses five key steps: (1) OffT identification through in silico complementarity prediction and transcriptomics analysis, (2) focus on cell types with relevant ONT activity, (3) in vitro verification and margin assessment, (4) risk assessment based on the OffT biological role, and (5) management of unavoidable OffTs. The authors provide detailed considerations for various ONT classes, emphasizing the importance of ONT-specific factors such as chemistry, delivery systems, and tissue distribution in OffT evaluation. The article also explores the potential of machine learning models to enhance OffT prediction and discusses strategies for experimental verification and risk assessment. These updated recommendations aim to improve the safety profile of ONTs entering clinical trials and to manage unavoidable OffTs. The authors hope that these recommendations will serve as a valuable resource for ONT development and for the forthcoming finalization of the FDA draft guidance and the International Council for Harmonization S13 guidance on Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics.

7 May 2021 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
TNTom T. G. Nieskens
Tom T. G. Nieskens
OMOtto Magnusson
Otto Magnusson
PAPatrik Andersson
Patrik Andersson
MSMagnus Söderberg
Magnus Söderberg
MPMikael Persson
Mikael Persson
ASAnna-Karin Sjögren
Anna-Karin Sjögren

1 January 2022
Verified
Book Chapter
Open access
PDF file
PAPatrik Andersson
Patrik Andersson
During the last decade, therapeutic oligonucleotide drugs (OND) have witnessed a tremendous development in chemistry and mechanistic understanding that have translated into successful clinical applications. Depending on the specific OND mechanism, chemistry, and design, the DMPK and toxicity properties can vary significantly between different OND classes and delivery approaches, the latter including lipid formulations or conjugation approaches to enhance productive OND uptake. At the same time, with the only difference between compounds being the nucleobase sequence, ONDs with same mechanism of action, chemistry, and design show relatively consistent behavior, allowing certain extrapolations between compounds within an OND class. This chapter provides a summary of the most common toxicities, the improved mechanistic understanding and the safety assessment activities performed for therapeutic oligonucleotides during the drug discovery and development process. Several of the considerations described for therapeutic applications should also be of value for the scientists mainly using oligonucleotides as research tools to explore various biological processes.

21 January 2026 in International Journal of Toxicology
Verified
Journal Article
Open access
JSJennifer D Sisler
Jennifer D Sisler
PAPatrik Andersson
Patrik Andersson
ABAlan Brown
Alan Brown
CHCarole Harbison
Carole Harbison
OIOnyi Irrechukwu
Onyi Irrechukwu
THTod A Harper
Tod A Harper
Oligonucleotide therapeutics (ONTs) are a growing class of nucleic acid–based therapies with the potential to treat a variety of diseases through several different mechanisms of action (MoA). The most prevalent MoA entails the inhibition of therapeutically relevant levels of protein expression via mRNA degradation, exemplified by numerous approved ONTs. ONTs have unique physicochemical properties, pharmacokinetic characteristics, and MoAs that are distinct from other drug classes. The result can be a disconnect between the administered dose, plasma drug concentrations, pharmacodynamics, and toxicity. Thus, ONT development poses unique scientific and regulatory challenges that are not fully addressed by current International Council for Harmonisation (ICH) guidelines. The complexity of ONT development has recently been recognized with the acceptance of the new ICH topic proposal “ICH S13—Nonclinical Safety Evaluation of Oligonucleotide-based Therapeutics.” In preparation for the ICH S13 Step 2 public consultation period, the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) DruSafe ONT Working Group convened to identify and discuss key considerations for ONT development, and to communicate areas where regulatory clarity and harmonization are most needed. Specifically, these include strategies to assess off-target toxicities, safety pharmacology, general toxicity studies, First-In-Human dose selection, genotoxicity studies, reproductive and developmental toxicity studies, carcinogenicity assessments, and the appropriate use of a surrogate molecule in development. The intended goals of this paper are to provide a means for communicating input towards the ICH process and to provide a resource for assisting with the public review of the draft ICH S13 Guidance.